Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
Camrelizumab Combined With Chemotherapy for Adjuvant Treatment of Cervical Cancer Patients With Pathologically Confirmed Lymph Node Positivity After Stage Surgery: A Prospective, Single-Arm, Multicenter, Phase II Clinical Trial
Women's Hospital School Of Medicine Zhejiang University
59 participants
Mar 10, 2025
INTERVENTIONAL
Conditions
Summary
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Eligibility
Inclusion Criteria3
- Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;
- Positive PD-L1 expression;
- ECOG score ≤1
Exclusion Criteria5
- Positive parametrium or surgical margin;
- Incomplete radical surgery;
- Residual target lesions;
- Active autoimmune disease or autoimmune disease requiring systemic treatment;
- Previous treatment with immune checkpoint inhibitors.
Interventions
Camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07167160